Advertisement


Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

2022 ASCO Annual Meeting

Advertisement

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Ursula Matulonis: Ignace, it's great to see you. Congratulations on this abstract. I think it's one of the exciting abstracts of ASCO 2022, and thank you for presenting the results. So, tell us about this trial and about tisotumab vedotin and its mechanism of action. Ignace Vergote: Thank you for your compliment. The tisotumab vedotin is an antibody drug conjugate binding to tissue factor. Tissue factor is present in many tumors, but especially in cervical cancer. Almost always it's present. And like all antibody drug conjugates, it binds to tissue factor and then the active chemotherapy is monomethyl or Restatin-E, which is a chemotherapy which is used often in ADCs. Once it's incorporated in the cell, the antibody and the drug splits and cell death is the result, which also results in activation of the T-cells, which are promoted due to the apoptosis. This is also the reason why a combination with PD-L1 blockers is very interesting because, of course, in this way we get even a stronger immunological effect in addition to the chemotherapeutic effect. Ursula Matulonis: So, tell us about the three arms that you presented, and also the really exciting results that you presented that's come out of those arms. Ignace Vergote: Yeah. So the three arms which we have presented here is two in first line, recurrent cervical cancer, or advanced cervical cancer, stage four, usually. One cohort with tisotumab vedotin and carboplatin and one cohort with tisotumab vedotin and pembro. And the other is second line or third line. It's about three, three quarter second line, and the rest third line with tisotumab vedotin and pembrolizumab again. Ursula Matulonis: And tell us about, the results are quite striking in terms of the overall response rates. Ignace Vergote: Yes. In first line with tisotumab vedotin and carboplatin, we have a response rate of 55%, which is good. That's without pembro, without the bevacizumab. Like, when we compare to keynote A26, we have to take into account it's only two drugs. And very similar for, tisotumab vedotin and pembro and first line 41% response. And what is very interesting is that the response in the two cohorts with pembro is very long. We have follow-up of one and a half year almost. And the medium duration of response in the TV pembro is not even reached. And that's of course, something which we know with IOs. Also with siniprimot and second line. The responses, if there are responses, is very long. That a combination of the tisotumab vedotin and pembro, you see a higher response rate and a long response rate. More than one year. Ursula Matulonis: And I think most of the patients on the Pembro arm were PD-L1 positive? Ignace Vergote: Yes. That was about, depending on the cohort, between 85% and 91%. So, there were PD-L1 positive. We didn't select it for them, but we know that in cervical cancer about 90% is PD-L1 positive. So, that's concordant. Ursula Matulonis: It's very, it's very impressive results. So, tell us a little bit about the toxicities of tizonumab and then if you saw any unusual toxicities, when, when putting this drug together with either carboplatin or with, with pembro. Ignace Vergote: Well, I've been involved in tisotumab vedotin now for six, seven years already. I did the first in humans. The phase one I presented at ESMO, I think in 2017. The monotherapy, and then the consolidation trial, which led to the fast track approval of the monotherapy in second line. And in the beginning, the eye toxicity was more of a problem, especially when we gave tisotumab vedotin weekly. There was also cohort, but we learned how to treat this eye toxicity and how to prevent it with eye drops, with cooling pads on the eyes during the infusion. And so in this study, we have, I think, depending on the cohort, but we have about 3% grade three eye toxicity, but the main toxicities are grade one and two and quite quickly reversible now with these precautions. So, for the peripheral neuropathy, indeed, we see this as well. But, as you know we all have a lot of experience with paclitaxel and when I compare it, it's less and later. It's especially patients who are treated very long. We have been treating patients up to one year with tisotumab vedotin, and then you see it. Sometimes earlier, but it's mainly a late effect. And little bit different characteristics compared with what we know from paclitaxel. Ursula Matulonis: Next steps for tisotumab and cervical cancer? Ignace Vergote: Well, we are doing with GOG foundation, the ENGOT Cervix 12, which is a trial in second line with monotherapy and randomized phase three, which is running very well compared with the classical chemotherapies. So this is one thing. And then the other thing, of course, with these results, which we have presented here, we are doing a new cohort with the, with the triplet and the quadruplet. We have also presented that as a tip here, meaning tisotumab vedotin, carboplatin, pembro, and Bev. Or the triplets, if Bev is contraindicated. So, and this is of course the preparation of a first line trial as well. Ursula Matulonis: Congratulations. That makes perfect sense. It's it's a really active drug and thank you for your really significant role in, in starting the trials and getting to this time point for a cancer that really hasn't had much in terms of movement forward in terms of new treatments. And advances. So, so thank you so much. Ignace Vergote: Thank you.

Related Videos

Neuroendocrine Tumors

Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).

Breast Cancer

Ann H. Partridge, MD, MPH, and Kevin Kalinsky, MD, on Breast Cancer: Latest Findings on Fulvestrant or Exemestane With or Without Ribociclib

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative metastatic breast cancer when they switched to endocrine therapy and received ribociclib after disease progression on another CDK4/6 inhibitor (Abstract LBA1004).

Breast Cancer

Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).

Lung Cancer
Immunotherapy

Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy

Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant treatment for locally advanced, resectable stage IIIA non–small cell lung cancer (Abstract 8501).

Advertisement

Advertisement




Advertisement